GYL Financial Synergies LLC Takes $208,000 Position in Merck & Co., Inc. (NYSE:MRK)

GYL Financial Synergies LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,500 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds also recently made changes to their positions in the company. O Brien Wealth Partners LLC lifted its stake in shares of Merck & Co., Inc. by 4.2% in the first quarter. O Brien Wealth Partners LLC now owns 3,281 shares of the company’s stock valued at $273,000 after buying an additional 133 shares in the last quarter. Peoples Bank OH raised its holdings in shares of Merck & Co., Inc. by 1.7% in the fourth quarter. Peoples Bank OH now owns 8,245 shares of the company’s stock valued at $630,000 after purchasing an additional 140 shares during the last quarter. Maple Capital Management Inc. raised its holdings in shares of Merck & Co., Inc. by 0.7% in the fourth quarter. Maple Capital Management Inc. now owns 21,536 shares of the company’s stock valued at $1,646,000 after purchasing an additional 147 shares during the last quarter. Resources Management Corp CT ADV raised its holdings in shares of Merck & Co., Inc. by 0.8% in the fourth quarter. Resources Management Corp CT ADV now owns 19,836 shares of the company’s stock valued at $1,515,000 after purchasing an additional 151 shares during the last quarter. Finally, Atlas Capital Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 11.1% in the fourth quarter. Atlas Capital Advisors LLC now owns 1,528 shares of the company’s stock valued at $117,000 after purchasing an additional 153 shares during the last quarter. 75.08% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently commented on the stock. Bank of America set a $97.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research downgraded shares of Hudson Technologies from a “hold” rating to a “sell” rating in a report on Monday, April 1st. Morgan Stanley restated a “hold” rating on shares of PG&E in a report on Friday, June 21st. UBS Group raised their price objective on shares of Tableau Software to $134.00 and gave the stock a “neutral” rating in a report on Thursday, May 2nd. Finally, Citigroup lifted their target price on shares of from GBX 1,300 ($16.99) to GBX 1,450 ($18.95) and gave the stock a “buy” rating in a research note on Friday, June 21st. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $87.67.

In other news, CFO Robert M. Davis sold 216,718 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the completion of the sale, the chief financial officer now owns 354,378 shares of the company’s stock, valued at approximately $30,274,512.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard R. Deluca sold 35,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $80.00, for a total transaction of $2,800,000.00. Following the sale, the executive vice president now directly owns 106,064 shares of the company’s stock, valued at approximately $8,485,120. The disclosure for this sale can be found here. Insiders have sold a total of 276,718 shares of company stock valued at $23,257,469 in the last ninety days. Insiders own 0.27% of the company’s stock.

Merck & Co., Inc. stock traded down $1.27 during mid-day trading on Friday, reaching $79.73. The stock had a trading volume of 18,044,510 shares, compared to its average volume of 11,342,410. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a market cap of $208.55 billion, a P/E ratio of 17.96, a price-to-earnings-growth ratio of 1.73 and a beta of 0.57. The company’s 50-day moving average price is $82.99. Merck & Co., Inc. has a one year low of $62.01 and a one year high of $87.07.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, April 30th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.17. The business had revenue of $10.82 billion for the quarter, compared to analysts’ expectations of $10.45 billion. Merck & Co., Inc. had a net margin of 19.50% and a return on equity of 39.85%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.05 EPS. On average, analysts forecast that Merck & Co., Inc. will post 4.74 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, July 8th. Stockholders of record on Monday, June 17th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.76%. The ex-dividend date of this dividend was Friday, June 14th. Merck & Co., Inc.’s payout ratio is currently 50.69%.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Can systematic risk be avoided?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.